Welcome to our dedicated page for Crinetics Pharmaceuticals SEC filings (Ticker: CRNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing a biotech 10-K crammed with receptor pharmacology, clinical trial endpoints, and R&D burn rates can feel impossible. Crinetics Pharmaceuticals’ disclosures are especially dense because every milestone for paltusotine and atumelnant must be documented in detail. If you have ever wondered, “Where do I find Crinetics Pharmaceuticals insider trading Form 4 transactions before the market reacts?” or “How do I extract trial-stage spending from their quarterly earnings report 10-Q filing?”, you are in the right place.
Stock Titan applies AI-powered summaries to every Crinetics filing—turning 250-page documents into clear takeaways in seconds. Get real-time alerts the moment a Crinetics Pharmaceuticals Form 4 insider transactions real-time update hits EDGAR. Drill into each Crinetics Pharmaceuticals annual report 10-K simplified for R&D cost trends, or scan a Crinetics Pharmaceuticals proxy statement executive compensation to see how stock awards align with endocrine-drug milestones. Our coverage spans all forms: 8-K material events explained (trial data releases or FDA designations), S-3 capital raises, definitive proxies, plus every Crinetics Pharmaceuticals quarterly earnings report 10-Q filing with side-by-side earnings report filing analysis.
Use cases are practical: monitor executive stock transactions Form 4 for confidence signals before pivotal data; compare sequential IGF-1 efficacy figures without reading every footnote; or simply bookmark understanding Crinetics Pharmaceuticals SEC documents with AI to save hours each quarter. Whether you need Crinetics Pharmaceuticals SEC filings explained simply or a granular look at endocrine program risks, our platform delivers complete coverage—updated in real time and decoded for fast, informed decisions.
Crinetics Pharmaceuticals (Nasdaq:CRNX) furnished an 8-K covering its June 26 2025 R&D Day. Management unveiled new pre-clinical data on three assets—TSHR antagonist CRN12755 for Graves’ disease, SST3 agonist CRN10329 for ADPKD and drug-conjugate CRN09682 for SST2-positive tumors—and outlined the Phase 1/2 BRAVESST2 design enrolling up to 150 patients. Highlights include reductions in thyroid hormone, hyaluronic acid, IL-6 and cystic indices, plus dose-dependent anti-tumor activity. No financial results or guidance were provided; information is “furnished,” not “filed,” and forward-looking statements stress clinical, regulatory and financing risks.
FAQ
What is the current stock price of Crinetics Pharmaceuticals (CRNX)?
What is the market cap of Crinetics Pharmaceuticals (CRNX)?
What is the primary focus of Crinetics Pharmaceuticals?
Which key conditions are targeted by Crinetics' drug candidates?
What makes paltusotine unique as a therapeutic agent?
How does atumelnant differ from traditional treatments?
What is the advantage of oral small molecule therapeutics?
How does Crinetics demonstrate its expertise in drug discovery?
What are the key competitive advantages of Crinetics Pharmaceuticals?
Which market segments does Crinetics serve?
